Cardiovascular Diabetology最新文献

筛选
英文 中文
Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial. 恩格列净与2型糖尿病合并冠心病患者的左心房功能:EMPA-HEART CardioLink-6随机临床试验的启示。
IF 8.5 1区 医学
Cardiovascular Diabetology Pub Date : 2024-08-28 DOI: 10.1186/s12933-024-02344-6
Marina Pourafkari, Kim A Connelly, Subodh Verma, C David Mazer, Hwee Teoh, Adrian Quan, Shaun G Goodman, Archana Rai, Ming Yen Ng, Djeven P Deva, Piero Triverio, Laura Jiminez-Juan, Andrew T Yan, Yin Ge
{"title":"Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial.","authors":"Marina Pourafkari, Kim A Connelly, Subodh Verma, C David Mazer, Hwee Teoh, Adrian Quan, Shaun G Goodman, Archana Rai, Ming Yen Ng, Djeven P Deva, Piero Triverio, Laura Jiminez-Juan, Andrew T Yan, Yin Ge","doi":"10.1186/s12933-024-02344-6","DOIUrl":"10.1186/s12933-024-02344-6","url":null,"abstract":"<p><strong>Background: </strong>Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated reduction in heart failure outcomes in patients with type 2 diabetes mellitus, although the exact mechanism of benefit remains unclear. Alteration in left atrial (LA) function due to chronic pressure or volume overload is a hallmark of heart failure.</p><p><strong>Objective: </strong>To evaluate the effect of the SGLT2 inhibitor empagliflozin on LA volume and function.</p><p><strong>Methods: </strong>90 patients with coronary artery disease and type 2 diabetes (T2DM) were randomized to empagliflozin (n = 44) or placebo (n = 46), and underwent cardiac magnetic resonance (CMR) imaging at baseline and after 6 months. The main outcome was change in LA volume; LA function, including active and passive components, was also measured by a blinded reader.</p><p><strong>Results: </strong>At baseline, there was no significant difference in LA volumes between the empagliflozin (indexed maximum LA volume 26.4 ± 8.4mL/m<sup>2</sup>, minimum LA volume 11.1 ± 5.7mL/m<sup>2</sup>) and placebo (indexed maximum LA volume 28.7 ± 8.2mL/m<sup>2</sup>, minimum LA volume 12.6 ± 5.0mL/m<sup>2</sup>) groups. After 6 months, changes in LA volumes did not differ with adjusted difference (empagliflozin minus placebo): 0.99 mL/m<sup>2</sup> (95% CI: -1.7 to 3.7 mL/m<sup>2</sup>; p = 0.47) for indexed maximum LA volume, and 0.87 mL/m<sup>2</sup> (95% CI: -0.9 to 2.6 mL/m<sup>2</sup>; p = 0.32) for indexed minimum LA volume. Changes in total LA emptying fraction were also similar, with between-group adjusted mean difference - 0.01 (95% CI: -0.05 to 0.03, p = 0.59).</p><p><strong>Conclusion: </strong>SGLT2 inhibition with empagliflozin for 6 months did not have a significant impact on LA volume and function in patients with T2DM and coronary artery disease. (Effects of Empagliflozin on Cardiac Structure in Patients with Type 2 Diabetes [EMPA-HEART]; NCT02998970).</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11360285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142092247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Additive effect of metabolic dysfunction-associated fatty liver disease on left ventricular function and global strain in type 2 diabetes mellitus patients: a 3.0 T cardiac magnetic resonance feature tracking study. 代谢功能障碍相关脂肪肝对 2 型糖尿病患者左心室功能和整体应变的叠加效应:3.0 T 心脏磁共振特征追踪研究。
IF 8.5 1区 医学
Cardiovascular Diabetology Pub Date : 2024-08-27 DOI: 10.1186/s12933-024-02410-z
Xin Tang, Rui Shi, Li Jiang, Wei-Feng Yan, Pei-Lun Han, Wen-Lei Qian, Zhi-Gang Yang, Yuan Li
{"title":"Additive effect of metabolic dysfunction-associated fatty liver disease on left ventricular function and global strain in type 2 diabetes mellitus patients: a 3.0 T cardiac magnetic resonance feature tracking study.","authors":"Xin Tang, Rui Shi, Li Jiang, Wei-Feng Yan, Pei-Lun Han, Wen-Lei Qian, Zhi-Gang Yang, Yuan Li","doi":"10.1186/s12933-024-02410-z","DOIUrl":"10.1186/s12933-024-02410-z","url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes mellitus (T2DM) and metabolic-associated fatty liver disease (MAFLD) are both metabolic disorders that negatively impact the cardiovascular system. This study comprehensively analyzed the additive effect of MAFLD on left ventricular function and global strain in T2DM patients by cardiac magnetic resonance (CMR).</p><p><strong>Methods: </strong>Data of 261 T2DM patients, including 109 with and 152 without MAFLD, as well as 73 matched normal controls from our medical center between June 2015 and March 2022 were retrospectively analyzed. CMR-derived parameters, including LV function and global strain parameters, were compared among different groups. Univariate and multivariate linear regression analyses were conducted to investigate the impact of various factors on LV function and global strain.</p><p><strong>Results: </strong>Our investigation revealed a progressive deterioration in LV functional parameters across three groups: control subjects, T2DM patients without MAFLD, and T2DM patients with MAFLD. Statistically significant increases in left ventricular end-diastolic volume index (LVEDVI), left ventricular end-systolic volume index (LVESVI), left ventricular mass index (LVMI) were observed, along with decreases in left ventricular ejection fraction (LVEF) and left ventricular global function index (LVGFI). Among these three groups, significant reductions were also noted in the absolute values of LV global radial, circumferential, and longitudinal peak strains (GRPS, GCPS, and GLPS), as well as in peak systolic (PSSR) and peak diastolic strain rates (PDSR). MAFLD was identified as an independent predictor of LVEF, LVMI, LVGFI, GRPS, GCPS, and GLPS in multivariate linear analysis. Besides, the incidence of late gadolinium enhancement was higher in MAFLD patients than in non-MAFLD patients (50/109 [45.9%] vs. 42/152 [27.6%], p = 0.003). Furthermore, escalating MAFLD severity was associated with a numerical deterioration in both LV function parameters and global strain values.</p><p><strong>Conclusions: </strong>This study thoroughly compared CMR parameters in T2DM patients with and without MAFLD, uncovering MAFLD's adverse impact on LV function and deformation in T2DM patients. These findings highlight the critical need for early detection and comprehensive management of cardiac function in T2DM patients with MAFLD.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying metabotypes of insulin resistance severity in children with metabolic syndrome. 确定代谢综合征儿童胰岛素抵抗严重程度的代谢类型。
IF 8.5 1区 医学
Cardiovascular Diabetology Pub Date : 2024-08-27 DOI: 10.1186/s12933-024-02412-x
Álvaro González-Domínguez, Jesús Domínguez-Riscart, Otto Savolainen, Alfonso Lechuga-Sancho, Rikard Landberg, Raúl González-Domínguez
{"title":"Identifying metabotypes of insulin resistance severity in children with metabolic syndrome.","authors":"Álvaro González-Domínguez, Jesús Domínguez-Riscart, Otto Savolainen, Alfonso Lechuga-Sancho, Rikard Landberg, Raúl González-Domínguez","doi":"10.1186/s12933-024-02412-x","DOIUrl":"10.1186/s12933-024-02412-x","url":null,"abstract":"<p><strong>Background: </strong>Insulin resistance is a frequent precursor of typical obesity and metabolic syndrome complications. However, accurate diagnosis remains elusive because of its pathophysiological complexity and heterogeneity. Herein, we have explored the utility of insulin secretion dynamics in response to an oral glucose tolerance test as a surrogate marker to identify distinct metabotypes of disease severity.</p><p><strong>Methods: </strong>The study population consisted of children with obesity and insulin resistance, stratified according to the post-challenge insulin peak timing (i.e., early, middle, and late peak), from whom fasting and postprandial plasma and erythrocytes were collected for metabolomics analysis.</p><p><strong>Results: </strong>Children with late insulin peak manifested worse cardiometabolic health (i.e., higher blood pressure, glycemia, and HOMA-IR scores) than early responders. These subjects also showed more pronounced changes in metabolites mirroring failures in energy homeostasis, oxidative stress, metabolism of cholesterol and phospholipids, and adherence to unhealthy dietary habits. Furthermore, delayed insulin peak was associated with impaired metabolic flexibility, as reflected in compromised capacity to regulate mitochondrial energy pathways and the antioxidant defense in response to glucose overload.</p><p><strong>Conclusions: </strong>Altogether, these findings suggest that insulin resistance could encompass several phenotypic subtypes characterized by graded disturbances in distinctive metabolic derangements occurring in childhood obesity, which serve as severity predictive markers.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adiposity modifies the association between heart failure risk and glucose metabolic disorder in older individuals: a community-based prospective cohort study. 肥胖会改变老年人心力衰竭风险与葡萄糖代谢紊乱之间的关系:一项基于社区的前瞻性队列研究。
IF 8.5 1区 医学
Cardiovascular Diabetology Pub Date : 2024-08-27 DOI: 10.1186/s12933-024-02418-5
Liming Hou, Xin Wang, Peilin Li, Hua Zhang, Yanli Yao, Zhendong Liu, Juan Wang, Weike Liu
{"title":"Adiposity modifies the association between heart failure risk and glucose metabolic disorder in older individuals: a community-based prospective cohort study.","authors":"Liming Hou, Xin Wang, Peilin Li, Hua Zhang, Yanli Yao, Zhendong Liu, Juan Wang, Weike Liu","doi":"10.1186/s12933-024-02418-5","DOIUrl":"10.1186/s12933-024-02418-5","url":null,"abstract":"<p><strong>Background: </strong>Glucose metabolic disorder is associated with the risk of heart failure (HF). Adiposity is a comorbidity that is inextricably linked with abnormal glucose metabolism in older individuals. However, the effect of adiposity on the association between glucose metabolic disorder and HF risk, and the underlying mechanism remain unclear.</p><p><strong>Methods: </strong>A total of 13,251 participants aged ≥ 60 years from a cohort study were categorized into euglycemia, prediabetes, uncontrolled diabetes, and well-controlled diabetes. Adiposity was assessed using body mass index (BMI), waist-to-hip ratio (WHR), and visceral fat area (VFA). Adiposity-associated metabolic activities were evaluated using adiponectin-to-leptin ratio (ALR), homeostatic model assessment of insulin resistance (HOMA-IR), and triglyceride-glucose index (TyG). The first occurrence of HF served as the outcome during the follow-up period.</p><p><strong>Results: </strong>A total of 1,138 participants developed HF over the course of an average follow-up period of 10.9 years. The rate of incident HF occurrence was higher in prediabetes, uncontrolled diabetes, and well-controlled diabetes participants compared to that in euglycemia participants. However, the high rates were significantly attenuated by BMI, VFA, and WHR. For WHR in particular, the hazard ratio for incident HF was 1.18 (95% confidence interval (CI): 1.03, 1.35, P<sub>adj.</sub>=0.017) in prediabetes, 1.59 (95% CI: 1.34, 1.90, P<sub>adj.</sub><0.001) in uncontrolled diabetes, and 1.10 (95% CI: 0.85, 1.43, P<sub>adj.</sub>=0.466) in well-controlled diabetes. The population attributable risk percentage for central obesity classified by WHR for incident HF was 30.3% in euglycemia, 50.0% in prediabetes, 48.5% in uncontrolled diabetes, and 54.4% in well-controlled diabetes. Adiposity measures, especially WHR, showed a significant interaction with glucose metabolic disorder in incident HF (all P<sub>adj.</sub><0.001). ALR was negatively associated and HOMA-IR and TyG were positively associated with BMI, WHR, VFA, and incident HF (all P<sub>adj.</sub><0.05). ALR, HOMA-IR, and TyG mediated the associations for BMI, WHR and VFA with incident HF (all P<sub>adj</sub>.<0.05).</p><p><strong>Conclusions: </strong>Adiposity attenuated the association of glucose metabolic disorder with incident HF. The results also showed that WHR may be an appropriate indicator for evaluating adiposity in older individuals. Adiposity-associated metabolic activities may have a bridging role in the process of adiposity attenuating the association between glucose metabolic disorder and incident HF.</p><p><strong>Trial registration: </strong>retrospectively registered number: ChiCTR-EOC-17,013,598.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic effect of the TyG index on patients with severe aortic stenosis following transcatheter aortic valve replacement: a retrospective cohort study. 经导管主动脉瓣置换术后,TyG 指数对重度主动脉瓣狭窄患者的预后影响:一项回顾性队列研究。
IF 8.5 1区 医学
Cardiovascular Diabetology Pub Date : 2024-08-24 DOI: 10.1186/s12933-024-02414-9
Weiya Li, Hongde Li, Shiqin Peng, Junli Li, Yuan Feng, Yong Peng, Jiafu Wei, Zhengang Zhao, Tianyuan Xiong, Haoran Yang, Chengxiang Song, Lin Bai, Yijun Yao, Fei Chen, Yue Yin, Mao Chen
{"title":"Prognostic effect of the TyG index on patients with severe aortic stenosis following transcatheter aortic valve replacement: a retrospective cohort study.","authors":"Weiya Li, Hongde Li, Shiqin Peng, Junli Li, Yuan Feng, Yong Peng, Jiafu Wei, Zhengang Zhao, Tianyuan Xiong, Haoran Yang, Chengxiang Song, Lin Bai, Yijun Yao, Fei Chen, Yue Yin, Mao Chen","doi":"10.1186/s12933-024-02414-9","DOIUrl":"10.1186/s12933-024-02414-9","url":null,"abstract":"<p><strong>Background: </strong>The triglyceride glucose (TyG) index, as a reliable marker of insulin resistance, is associated with the incidence and poor prognosis of various cardiovascular diseases. However, the relationship between the TyG index and clinical outcomes in patients with severe aortic stenosis (AS) who underwent transcatheter aortic valve replacement (TAVR) remains unclear.</p><p><strong>Methods: </strong>This study consecutively enrolled 1569 patients with AS underwent TAVR at West China Hospital of Sichuan University between April 2014 and August 2023. The outcomes of interest included all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events (MACE). Multivariate adjusted Cox regression and restricted cubic splines (RCS) regression analyses were used to assess the associations between the TyG index and the clinical outcomes. The incremental prognostic value of the TyG index was further assessed by the time-dependent Harrell's C-index, integrated discrimination improvement (IDI) and the net reclassification improvement (NRI).</p><p><strong>Results: </strong>During a median follow-up of 1.09 years, there were 146, 70, and 196 patients experienced all-cause death, cardiovascular death, and MACE, respectively. After fully adjusting for confounders, a per-unit increase of TyG index was associated with a 441% (adjusted HR: 5.41, 95% CI: 4.01-7.32), 385% (adjusted HR: 4.85, 95% CI: 3.16-7.43), and 347% (adjusted HR: 4.47, 95% CI: 3.42-5.85) higher risk of all-cause mortality, cardiovascular mortality and MACE, respectively. The RCS regression analyses revealed a linear association between TyG index and endpoints (all P for non-linearity > 0.05) with 8.40 as the optimal binary cutoff point. Furthermore, adding TyG index to the basic risk model provided a significant incremental value in predicting poor prognosis (Time-dependent Harrell's C-index increased for all the endpoints; All-cause mortality, IDI: 0.11, P < 0.001; NRI: 0.32, P < 0.001; Cardiovascular mortality, IDI: 0.043, P < 0.001; NRI: 0.37, P < 0.001; MACE, IDI: 0.092, P < 0.001; NRI: 0.32, P < 0.001).</p><p><strong>Conclusions: </strong>In patients with severe AS receiving TAVR, there was a positive linear relationship between TyG index and poor prognosis, with 8.4 as the optimal bivariate cutoff value. Our findings suggest TyG index holds potential value for risk stratification and guiding therapeutic decisions in patients after TAVR.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11344917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bone proteins are associated with cardiovascular risk according to the SCORE2-Diabetes algorithm. 根据 SCORE2-糖尿病算法,骨蛋白与心血管风险有关。
IF 8.5 1区 医学
Cardiovascular Diabetology Pub Date : 2024-08-24 DOI: 10.1186/s12933-024-02406-9
Sheila González-Salvatierra, Antonia García-Martín, Beatriz García-Fontana, Luis Martínez-Heredia, Cristina García-Fontana, Manuel Muñoz-Torres
{"title":"Bone proteins are associated with cardiovascular risk according to the SCORE2-Diabetes algorithm.","authors":"Sheila González-Salvatierra, Antonia García-Martín, Beatriz García-Fontana, Luis Martínez-Heredia, Cristina García-Fontana, Manuel Muñoz-Torres","doi":"10.1186/s12933-024-02406-9","DOIUrl":"10.1186/s12933-024-02406-9","url":null,"abstract":"<p><strong>Background: </strong>Typical bone proteins, such as sclerostin and periostin, have been associated with cardiovascular disease (CVD). Simultaneously, several risk scores have been developed to predict CVD in the general population. Therefore, we aimed to evaluate the association of these bone proteins related to CVD, with the main vascular risk scales: Framingham Risk Score (FRS), REGICOR and SCORE2-Diabetes, in patients with type 2 diabetes. We focus in particular on the SCORE2-Diabetes algorithm, which predicts 10-year CVD risk and is specific to the study population.</p><p><strong>Methods: </strong>This was a cross-sectional study including 104 patients with type 2 diabetes (62 ± 6 years, 60% males). Clinical data, biochemical measurements, and serum bioactive sclerostin and periostin levels were collected, and different risk scales were calculated. The association between bioactive sclerostin or periostin with the risk scales was analyzed.</p><p><strong>Results: </strong>A positive correlation was observed between circulating levels of bioactive sclerostin (p < 0.001) and periostin (p < 0.001) with SCORE2-Diabetes values. However, no correlation was found with FRS or REGICOR scales. Both serum bioactive sclerostin and periostin levels were significantly elevated in patients at high-very high risk of CVD (score ≥ 10%) than in the low-moderate risk group (score < 10%) (p < 0.001 for both). Moreover, analyzing these proteins to identify patients with type 2 diabetes at high-very high vascular risk using ROC curves, we observed significant AUC values for bioactive sclerostin (AUC = 0.696; p = 0.001), periostin (AUC = 0.749; p < 0.001), and the model combining both (AUC = 0.795; p < 0.001). For diagnosing high-very high vascular risk, serum bioactive sclerostin levels > 131 pmol/L showed 51.6% sensitivity and 78.6% specificity. Similarly, serum periostin levels > 1144 pmol/L had 64.5% sensitivity and 76.2% specificity.</p><p><strong>Conclusions: </strong>Sclerostin and periostin are associated with vascular risk in the SCORE2-Diabetes algorithm, opening a new line of investigation to identify novel biomarkers of cardiovascular risk in the type 2 diabetes population.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11344922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 diabetes and chronic kidney disease: a randomized pilot trial. 五氧嘧啶可改善 2 型糖尿病和慢性肾病患者亚临床动脉粥样硬化的进展:一项随机试验。
IF 8.5 1区 医学
Cardiovascular Diabetology Pub Date : 2024-08-24 DOI: 10.1186/s12933-024-02393-x
Javier Donate-Correa, Carla M Ferri, Carmen Mora-Fernández, Nayra Pérez-Delgado, Ainhoa González-Luis, Juan F Navarro-González
{"title":"Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 diabetes and chronic kidney disease: a randomized pilot trial.","authors":"Javier Donate-Correa, Carla M Ferri, Carmen Mora-Fernández, Nayra Pérez-Delgado, Ainhoa González-Luis, Juan F Navarro-González","doi":"10.1186/s12933-024-02393-x","DOIUrl":"10.1186/s12933-024-02393-x","url":null,"abstract":"<p><strong>Background: </strong>Diabetic kidney disease (DKD) is associated with a higher risk of cardiovascular disease (CVD). Pentoxifylline (PTF), a nonselective phosphodiesterase inhibitor with anti-inflammatory, antiproliferative, and antifibrotic actions, has demonstrated renal benefits in both clinical trials and meta-analyses. The present work aimed to study the effects of PTF on the progression of subclinical atherosclerosis (SA) in a population of patients with diabetes and moderate to severe chronic kidney disease (CKD).</p><p><strong>Methods: </strong>In this open-label, randomized controlled, prospective single-center pilot study the evolution of carotid intima-media thickness (CIMT) and ankle-brachial index (ABI) were determined in 102 patients with type 2 diabetes mellitus and CKD assigned to PTF, aspirin or control groups during 18 months. We also determined the variations in the levels of inflammatory markers and Klotho (KL), a protein involved in maintaining cardiovascular health, and their relationship with the progression of SA.</p><p><strong>Results: </strong>Patients treated with PTF presented a better evolution of CIMT, increased KL mRNA levels in peripheral blood cells (PBCs) and reduced the inflammatory state. The progression of CIMT values was inversely related to variations in KL both in serum and mRNA expression levels in PBCs. Multiple regression analysis demonstrated that PTF treatment and variations in mRNA KL expression in PBCs, together with changes in HDL, were significant determinants for the progression of CIMT (adjusted R<sup>2</sup> = 0.24, P < 0.001) independently of traditional risk factors. Moreover, both variables constituted protective factors against a worst progression of CIMT [OR: 0.103 (P = 0.001) and 0.001 (P = 0.005), respectively].</p><p><strong>Conclusions: </strong>PTF reduced SA progression assessed by CIMT variation, a beneficial effect related to KL gene expression in PBCs.</p><p><strong>Trial registration: </strong>The study protocol code is PTF-AA-TR-2009 and the trial was registered on the European Union Drug Regulating Authorities Clinical Trials (EudraCT #2009-016595-77). The validation date was 2010-03-09.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11344929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An observational study of therapeutic procedures and in-hospital outcomes among patients admitted for acute myocardial infarction in Spain, 2016-2022: the role of diabetes mellitus. 2016-2022年西班牙急性心肌梗死住院患者治疗程序和院内预后观察研究:糖尿病的作用。
IF 8.5 1区 医学
Cardiovascular Diabetology Pub Date : 2024-08-24 DOI: 10.1186/s12933-024-02403-y
Jose M de-Miguel-Yanes, Rodrigo Jimenez-Garcia, Valentin Hernandez-Barrera, Javier de-Miguel-Diez, Ana Jimenez-Sierra, Jose J Zamorano-León, Natividad Cuadrado-Corrales, Ana Lopez-de-Andres
{"title":"An observational study of therapeutic procedures and in-hospital outcomes among patients admitted for acute myocardial infarction in Spain, 2016-2022: the role of diabetes mellitus.","authors":"Jose M de-Miguel-Yanes, Rodrigo Jimenez-Garcia, Valentin Hernandez-Barrera, Javier de-Miguel-Diez, Ana Jimenez-Sierra, Jose J Zamorano-León, Natividad Cuadrado-Corrales, Ana Lopez-de-Andres","doi":"10.1186/s12933-024-02403-y","DOIUrl":"10.1186/s12933-024-02403-y","url":null,"abstract":"<p><strong>Background: </strong>We used the Spanish national hospital discharge data from 2016 to 2022 to analyze procedures and hospital outcomes among patients aged ≥ 18 years admitted for ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) according to diabetes mellitus (DM) status (non-diabetic, type 1-DM or type 2-DM).</p><p><strong>Methods: </strong>We built logistic regression models for STEMI/NSTEMI stratified by DM status to identify variables associated with in-hospital mortality (IHM). We analyzed the effect of DM on IHM.</p><p><strong>Results: </strong>Spanish hospitals reported 201,950 STEMIs (72.7% non-diabetic, 0.5% type 1-DM, and 26.8% type 2-DM; 26.3% female) and 167,285 NSTEMIs (61.6% non-diabetic, 0.6% type 1-DM, and 37.8% type 2-DM; 30.9% female). In STEMI, the frequency of percutaneous coronary intervention (PCI) increased among non-diabetic people (60.4% vs. 68.6%; p < 0.001) and people with type 2-DM (53.6% vs. 66.1%; p < 0.001). In NSTEMI, the frequency of PCI increased among non-diabetic people (43.7% vs. 45.7%; p < 0.001) and people with type 2-DM (39.1% vs. 42.8%; p < 0.001). In NSTEMI, the frequency of coronary artery by-pass grafting (CABG) increased among non-diabetic people (2.8% vs. 3.5%; p < 0.001) and people with type 2-DM (3.7% vs. 5.0%; p < 0.001). In the entire population, lower IHM was associated with undergoing PCI (odds ratio [OR] [95% confidence interval] = 0.34 [0.32-0.35] in STEMI; 0.24 [0.23-0.26] in NSTEMI) or CABG (0.33 [0.27-0.40] in STEMI; 0.45 [0.38-0.53] in NSTEMI). IHM decreased over time in STEMI (OR = 0.86 [0.80-0.93]). Type 2-DM was associated with higher IHM in STEMI (OR = 1.06 [1.01-1.11]).</p><p><strong>Conclusions: </strong>PCI and CABG were associated with lower IHM in people admitted for STEMI/NSTEMI. Type 2-DM was associated with IHM in STEMI.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11344913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic and prognostic value of triglyceride glucose index: a comprehensive evaluation of meta-analysis. 甘油三酯葡萄糖指数的诊断和预后价值:荟萃分析的综合评估。
IF 8.5 1区 医学
Cardiovascular Diabetology Pub Date : 2024-08-23 DOI: 10.1186/s12933-024-02392-y
Sandeep Samethadka Nayak, Dona Kuriyakose, Lakshmi D Polisetty, Anjali Avinash Patil, Daniyal Ameen, Rakshita Bonu, Samatha P Shetty, Pubali Biswas, Micheal T Ulrich, Negin Letafatkar, Arman Habibi, Mohammad-Hossein Keivanlou, Sara Nobakht, Abdulhadi Alotaibi, Soheil Hassanipour, Ehsan Amini-Salehi
{"title":"Diagnostic and prognostic value of triglyceride glucose index: a comprehensive evaluation of meta-analysis.","authors":"Sandeep Samethadka Nayak, Dona Kuriyakose, Lakshmi D Polisetty, Anjali Avinash Patil, Daniyal Ameen, Rakshita Bonu, Samatha P Shetty, Pubali Biswas, Micheal T Ulrich, Negin Letafatkar, Arman Habibi, Mohammad-Hossein Keivanlou, Sara Nobakht, Abdulhadi Alotaibi, Soheil Hassanipour, Ehsan Amini-Salehi","doi":"10.1186/s12933-024-02392-y","DOIUrl":"10.1186/s12933-024-02392-y","url":null,"abstract":"<p><strong>Objective: </strong>The present umbrella review aims to collate and summarize the findings from previous meta-analyses on the Triglyceride and Glucose (TyG) Index, providing insights to clinicians, researchers, and policymakers regarding the usefulness of this biomarker in various clinical settings.</p><p><strong>Methods: </strong>A comprehensive search was conducted in PubMed, Scopus, and Web of Science up to April 14, 2024, without language restrictions. The AMSTAR2 checklist assessed the methodological quality of the included meta-analyses. Statistical analyses were performed using Comprehensive Meta-Analysis (CMA) software.</p><p><strong>Results: </strong>A total of 32 studies were finally included. The results revealed significant associations between the TyG index and various health outcomes. For kidney outcomes, a high TyG index was significantly associated with an increased risk of contrast-induced nephropathy (CIN) (OR = 2.24, 95% CI: 1.82-2.77) and chronic kidney disease (CKD) (RR = 1.46, 95% CI: 1.32-1.63). High TyG index was significantly associated with an increased risk of type 2 diabetes mellitus (T2DM) (RR = 3.53, 95% CI: 2.74-4.54), gestational diabetes mellitus (GDM) (OR = 2.41, 95% CI: 1.48-3.91), and diabetic retinopathy (DR) (OR = 2.34, 95% CI: 1.31-4.19). Regarding metabolic diseases, the TyG index was significantly higher in patients with obstructive sleep apnea (OSA) (SMD = 0.86, 95% CI: 0.57-1.15), metabolic syndrome (MD = 0.83, 95% CI: 0.74-0.93), and non-alcoholic fatty liver disease (NAFLD) (OR = 2.36, 95% CI: 1.88-2.97) compared to those without these conditions. In cerebrovascular diseases, a higher TyG index was significantly associated with an increased risk of dementia (OR = 1.14, 95% CI: 1.12-1.16), cognitive impairment (OR = 2.31, 95% CI: 1.38-3.86), and ischemic stroke (OR = 1.37, 95% CI: 1.22-1.54). For cardiovascular outcomes, the TyG index showed significant associations with an increased risk of heart failure (HF) (HR = 1.21, 95% CI: 1.12-1.30), atrial fibrillation (AF) (SMD = 1.22, 95% CI: 0.57-1.87), and hypertension (HTN) (RR = 1.52, 95% CI: 1.25-1.85).</p><p><strong>Conclusion: </strong>The TyG index is a promising biomarker for screening and predicting various medical conditions, particularly those related to insulin resistance and metabolic disorders. However, the heterogeneity and methodological quality of the included studies suggest the need for further high-quality research to confirm these findings and refine the clinical utility of the TyG index.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11344391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epicardial and liver fat implications in albuminuria: a retrospective study. 心外膜和肝脏脂肪对白蛋白尿的影响:一项回顾性研究。
IF 8.5 1区 医学
Cardiovascular Diabetology Pub Date : 2024-08-22 DOI: 10.1186/s12933-024-02399-5
Carolina M Perdomo, Nerea Martin-Calvo, Ana Ezponda, Francisco J Mendoza, Gorka Bastarrika, Nuria Garcia-Fernandez, José I Herrero, Inmaculada Colina, Javier Escalada, Gema Frühbeck
{"title":"Epicardial and liver fat implications in albuminuria: a retrospective study.","authors":"Carolina M Perdomo, Nerea Martin-Calvo, Ana Ezponda, Francisco J Mendoza, Gorka Bastarrika, Nuria Garcia-Fernandez, José I Herrero, Inmaculada Colina, Javier Escalada, Gema Frühbeck","doi":"10.1186/s12933-024-02399-5","DOIUrl":"10.1186/s12933-024-02399-5","url":null,"abstract":"<p><strong>Background: </strong>Albuminuria is considered an early and sensitive marker of kidney dysfunction, but also an independent cardiovascular risk factor. Considering the possible relationship among metabolic liver disease, cardiovascular disease and chronic kidney disease, we aimed to evaluate the risk of developing albuminuria regarding the presence of epicardial adipose tissue and the steatotic liver disease status.</p><p><strong>Methods: </strong>A retrospective long-term longitudinal study including 181 patients was carried out. Epicardial adipose tissue and steatotic liver disease were assessed by computed tomography. The presence of albuminuria at follow-up was defined as the outcome.</p><p><strong>Results: </strong>After a median follow up of 11.2 years, steatotic liver disease (HR 3.15; 95% CI, 1.20-8.26; p = 0.02) and excess amount of epicardial adipose tissue (HR 6.12; 95% CI, 1.69-22.19; p = 0.006) were associated with an increased risk of albuminuria after adjustment for visceral adipose tissue, sex, age, weight status, type 2 diabetes, prediabetes, hypertriglyceridemia, hypercholesterolemia, arterial hypertension, and cardiovascular prevention treatment at baseline. The presence of both conditions was associated with a higher risk of developing albuminuria compared to having steatotic liver disease alone (HR 5.91; 95% CI 1.15-30.41, p = 0.033). Compared with the first tertile of visceral adipose tissue, the proportion of subjects with liver steatosis and abnormal epicardial adipose tissue was significantly higher in the second and third tertile. We found a significant correlation between epicardial fat and steatotic liver disease (rho = 0.43 [p < 0.001]).</p><p><strong>Conclusions: </strong>Identification and management/decrease of excess adiposity must be a target in the primary and secondary prevention of chronic kidney disease development and progression. Visceral adiposity assessment may be an adequate target in the daily clinical setting. Moreover, epicardial adipose tissue and steatotic liver disease assessment may aid in the primary prevention of renal dysfunction.</p>","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11342567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信